2018 (4th) International Symposium on Next-Generation CAR & TCR-T Cells
Shanghai, Shanghai
Nov 23 - 24, 2018
Session Topic Start Time End Time Location Description Speakers
CAR-T, TCR-T, CAR-NK 23 Nov 09:00 AM 23 Nov 05:00 PM Shanghai, China Chimeric antigen receptors (CARs) are engineered receptors that combine a new specificity with an immune cell to target cancer cells. Typically, these receptors graft the specificity of a monoclonal antibody onto a T cell. The receptors are called chimeric because they are fused of parts from different sources. CAR-T cells are a new type of treatment that uses living cells that have been transformed.These T-cells are genetically engineered to express an artificial T cell receptor, through which they are targeted to disease-related antigens. This process is MHC independent and thus the targeting efficiency is greatly increased. Progress need to be made in treatment of solid tumors. Besides, CAR-T cells are developed to be specific to an antigen expressed on a tumor that is not expressed on healthy cells. Apart from these, novel cellular immunotherapies like TCR-T and CAR-NK are under development.